H.R. 1092 · 118th Congress · House

BENEFIT Act of 2023

Active· Referred to the Subcommittee on Health.
Introduced
Feb 17, 23
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023

This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Action Timeline

4
  1. FEB 24, 2023Committee

    Referred to the Subcommittee on Health.

  2. FEB 17, 2023IntroReferral

    Introduced in House

  3. FEB 17, 2023IntroReferral

    Introduced in House

  4. FEB 17, 2023IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

2

Health Subcommittee

hsif14

Referred: Feb 24, 2023

Active

Energy and Commerce Committee

hsif00

Referred: Feb 17, 2023

Active